MedTrace Logo

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

NCT06037577 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-09-14

No results posted yet for this study

Summary

CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). In this current study, the IP is tested in healthy male volunteers.

Conditions

  • Nonalcoholic Steatohepatitis (NASH)
  • Primary Sclerosing Cholangitis (PSC)
  • Systemic Sclerosis (SSc)

Interventions

DRUG

CM-101

Anti-human CCL24 monoclonal antibody (CM-101)

DRUG

Placebo

Placebo Comparator

Sponsors & Collaborators

  • ChemomAb Ltd.

    lead INDUSTRY

Principal Investigators

  • Arnon Aharon, MD · ChemomAb Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2019-05-05
Completion
2019-05-05

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06037577 on ClinicalTrials.gov